U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07435090) titled 'Efficacy and Safety of Rimegepant for Acute Dizziness' on Dec. 25, 2025.
Brief Summary: This study aims to explore the efficacy and safety of rimegepant for acute dizziness, including vestibular migraine (VM) and benign recurrent vertigo (BRV), through a multicenter, randomized controlled clinical trial. This study addresses the urgent clinical need for effective therapies for acute dizziness. Additionally, we will dynamically observe the changes in calcitonin gene-related peptide (CGRP) levels before and after treatment and explore the predictive value of CGRP levels for treatment efficacy and the prognosis of recurrence in patient...